Waxman Warns FDA Against Easing Guidance On Off-Label Promotions
This article was originally published in The Tan Sheet
Executive Summary
House Committee on Oversight and Government Reform Chairman Henry Waxman is urging FDA not to go forward with a guidance that he says would allow companies to use journal articles to promote off-label uses of drugs
You may also be interested in...
Genzyme Receives Complete Response, Warning Letters For Lumizyme
The hits just keep on coming for Genzyme. On a March 2 call with investors, the firm had to announce not just a "complete response" letter for its 2000-liter scale-up of Myozyme (which will be called Lumizyme for the larger production scale), but also that its Allston Landing manufacturing site had received a 483 report from FDA and a subsequent warning letter
Genzyme Receives Complete Response, Warning Letters For Lumizyme
Despite receiving a “complete response” letter and manufacturing warning letter on the same day, Genzyme remains upbeat about the likelihood of approval for its 2,000L scale-up of Myozyme.
Basilea Takes On Partner J&J In Arbitration Claim Over Ceftobiprole Delays
In an era where most product- and innovation-hungry big pharma firms have been desperately promoting themselves as "best partners," it is perhaps easy to forget what can go wrong when a biotech entrusts its asset to a larger firm